

22 September 2025

EVE COMMENCES DISTRIBUTION OF DYSPRO™

- Dyspro™ successfully manufactured at Australian GMP-certified facility and now being dispatched to distribution partners.
- Ready for prescription through TeleDocs' telehealth network.
- Additional access pathways under evaluation to expand reach and scalability.
- Dysmenorrhoea and endometriosis represent substantial unmet medical needs, with global treatment markets expected to exceed USD 20 billion by 2035.

EVE Health Group Limited (ASX: EVE, EVE or the Company) is pleased to announce that its proprietary women's health product, Dyspro™, has successfully completed GMP manufacture and is now being dispatched to distribution partners in preparation for its Australian launch.

Dyspro™ is a first-in-class cannabinoid-based gummy developed by EVE to support women experiencing dysmenorrhoea (painful menstruation) and endometriosis, two of the most prevalent and under-addressed conditions in women's health. Following the completion of commercial-scale production, Dyspro™ is now available for prescription under established regulatory pathways, with the first patient access expected shortly.

TeleDocs Partnership and Expanded Access

EVE has established a national prescribing and education partnership with TeleDocs Clinic, providing streamlined access through a trusted digital health platform and a network of more than 3,500 pharmacies across Australia. This collaboration ensures Dyspro™ can be prescribed via digital consults and dispensed efficiently across the country.

EVE is also evaluating additional prescribing and distribution partnerships to diversify patient access pathways and support future export opportunities.

EVE Executive Director and Chief Scientific Officer, Dr Stuart Gunzburg, said: "Moving Dyspro™ from the laboratory to large-scale manufacture and into distribution marks a transformational moment for EVE. We are now on the verge of bringing real relief to women experiencing painful and often debilitating menstrual symptoms. We look forward to broadening access pathways to ensure Dyspro™ can reach as many patients as possible."

Background on Dysmenorrhoea and Endometriosis

Dysmenorrhoea is a highly prevalent condition among Australian women of reproductive age. A recent study found that 77% of women aged 18–44 reported experiencing bothersome menstrual

symptoms, with 44% reporting missed days of work or study.¹ The annual burden of menstrual symptoms in Australia is estimated at AUD \$14.2 billion, largely due to lost productivity.

In more severe cases, dysmenorrhoea is associated with endometriosis, a chronic inflammatory condition estimated to affect up to 14% of reproductive-age women. A national survey found the average annual cost of illness per woman with chronic pelvic pain (with or without endometriosis) ranged from US\$16,970 to US\$20,898, with 75–84% of costs attributed to lost productivity.²

Market Opportunity

Dysmenorrhoea and endometriosis are highly prevalent and under-addressed women's health conditions, representing a substantial and growing global treatment market.

- The global dysmenorrhoea treatment market reached USD 10.9 billion in 2024 across the top seven pharmaceutical markets (US, EU4, UK, and Japan) and is forecast to grow at a CAGR of 5.73% to reach USD 20.0 billion by 2035.³
- In parallel, the Australian endometriosis treatment market is projected to reach USD 76.4 million by 2030, growing at a CAGR of 13% from 2025.⁴

Authorised for release by the Board of Directors.

Company enquiries

+61 8 6465 5500

info@evehealthgroup.com.au

About EVE Health Group

EVE Health Group (ASX: EVE) is an Australian-based health company developing and commercialising evidence-based wellness and pharmaceutical products. Through its subsidiaries Meluka Australia and Nexttract EVE delivers science-led innovations designed to support consumer and practitioner health across retail, pharmacy and clinical channels.

For further information, please visit www.evehealthgroup.com.au and follow us on LinkedIn.

¹ Mardon A.K. et al. *Problematic Periods: Casting Young Women—The Impact of Menstrual Symptoms on Work and Study*, *Australian and New Zealand Journal of Obstetrics and Gynaecology*, 2024. <https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajog.13926>

² Armour M. et al. *The cost of illness and economic burden of endometriosis and chronic pelvic pain in Australia: A national online survey*, <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0223316> Figures in Armour et al. (2019) were originally reported in 2017 International dollars (Int \$), using purchasing power parity (PPP) to approximate US dollar values. These are expressed in USD here for clarity.

³ IMARC Group, *Dysmenorrhea Market Outlook 2025-2035*, www.imarcgroup.com/dysmenorrhea-market

⁴ Grand View Research, *Australia Endometriosis Treatment Market Outlook*, www.grandviewresearch.com/horizon/outlook/endometriosis-treatment-market/australia